Sedana Medical AB (publ) (STO:SEDANA)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 950.65M |
| Revenue (ttm) | 196.15M |
| Net Income (ttm) | -39.52M |
| Shares Out | 99.34M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 72,877 |
| Average Volume | 122,532 |
| Open | 9.70 |
| Previous Close | 9.57 |
| Day's Range | 9.09 - 9.70 |
| 52-Week Range | 8.20 - 18.32 |
| Beta | 0.76 |
| RSI | 47.22 |
| Earnings Date | Apr 15, 2026 |
About Sedana Medical AB
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; Sedaconda (Isoflurane) for sedation of mechanically ventilated adult patients during intensive care; and AnaConDa, a medical device enabling the adminis... [Read more]
Financial Performance
In 2025, Sedana Medical AB's revenue was 200.23 million, an increase of 12.01% compared to the previous year's 178.75 million. Losses were -59.24 million, 455.0% more than in 2024.
Financial StatementsNews
Sedana Medical AB (OSTO:SEDANA) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Sedana Medical AB (OSTO:SEDANA) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives
Q1 2026 Sedana Medical AB (publ) Earnings Call Transcript
Q1 2026 Sedana Medical AB (publ) Earnings Call Transcript
Sedana Medical AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a slight sales decline due to lower ICU occupancy and strikes, but profitability improved with positive group EBITDA and strong ex-U.S. margins. U.S. market entry remains on track, with NDA submission expected mid-year and early access programs underway.
Sedana Medical AB (OSTO:SEDANA) Q1 2026 Earnings Report Preview: What To Look For
Sedana Medical AB (OSTO:SEDANA) Q1 2026 Earnings Report Preview: What To Look For
Sedana Medical AB (OSTO:SEDANA) Q4 2025 Earnings Call Highlights: Record Sales and Strategic US ...
Sedana Medical AB (OSTO:SEDANA) Q4 2025 Earnings Call Highlights: Record Sales and Strategic US Market Progress
Q4 2025 Sedana Medical AB (publ) Earnings Call Transcript
Q4 2025 Sedana Medical AB (publ) Earnings Call Transcript
Sedana Medical AB Earnings Call Transcript: Q4 2025
Delivered record sales and first-ever positive ex-US EBITDA, driven by strong growth in Spain and improved margins from cost discipline. US pivotal trials succeeded, with FDA Fast Track and early access program; US launch expected in 2027 pending approval.
Sedana Medical AB (OSTO:SEDANA) Q4 2025: Everything You Need To Know Ahead Of Earnings
Sedana Medical AB (OSTO:SEDANA) Q4 2025: Everything You Need To Know Ahead Of Earnings
Sedana Medical AB (FRA:7D2A) Q3 2025 Earnings Call Highlights: Strong Sales Growth Amid Market ...
Sedana Medical AB (FRA:7D2A) Q3 2025 Earnings Call Highlights: Strong Sales Growth Amid Market Challenges
Q3 2025 Sedana Medical AB (publ) Earnings Call Transcript
Q3 2025 Sedana Medical AB (publ) Earnings Call Transcript
Sedana Medical AB Earnings Call Transcript: Q3 2025
Q3 sales were below expectations due to lower ICU admissions, but profitability improved and ex-U.S. EBITDA remained positive. U.S. market entry preparations are on track, with robust clinical data and an early access program supporting future growth.
Sedana Medical AB (OSTO:SEDANA) Q2 2025 Earnings Call Highlights: Record Sales and Strategic ...
Sedana Medical AB (OSTO:SEDANA) Q2 2025 Earnings Call Highlights: Record Sales and Strategic Advances Amid Market Challenges
Sedana Medical AB Earnings Call Transcript: Q2 2025
Record sales and improved profitability driven by strong growth in Germany and other direct markets, with positive clinical trial results and regulatory progress in the U.S. supporting future expansion. Gross margin remains stable, CapEx is down, and the company is on track to meet its full-year EBITDA target.
Sedana Medical AB Transcript: Study Result
Two large U.S. ICU trials confirmed isoflurane's non-inferiority to propofol for sedation, with significant opioid reduction and similar wake-up times. Trends favored isoflurane for ICU-free days and mortality, supporting a strong case for U.S. approval and commercial adoption.
Sedana Medical AB Earnings Call Transcript: Q1 2025
Record Q1 sales grew 18% year-over-year, with strong direct market performance and stable 71% gross margin. EBITDA improved, CapEx dropped, and the FDA approved an expanded access program in the US. Cash position remains solid at SEK 165 million.
Sedana Medical AB Transcript: Study Result
The SESAR study found higher mortality and fewer ventilator-free days with sevoflurane versus propofol in ARDS patients, likely due to over-sedation and renal toxicity. Isoflurane, in contrast, has shown a strong safety profile and clinical benefits, supporting ongoing commercial and regulatory confidence.
Sedana Medical AB (STU:7D2A) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Sedana Medical AB (STU:7D2A) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Q4 2024 Sedana Medical AB (publ) Earnings Call Transcript
Q4 2024 Sedana Medical AB (publ) Earnings Call Transcript
Sedana Medical AB Earnings Call Transcript: Q4 2024
Annual sales hit a record SEK 179 million, up 17% year-over-year, with strong growth in Spain, UK, and France. Both US pivotal trials met primary endpoints, supporting US entry plans, while ex-US business nears profitability and cash burn declines.
Sedana Medical AB (FRA:7D2A) Q3 2024 Earnings Call Highlights: Record Sales and Strategic Moves ...
Sedana Medical AB (FRA:7D2A) Q3 2024 Earnings Call Highlights: Record Sales and Strategic Moves Propel Growth
Q3 2024 Sedana Medical AB (publ) Earnings Call(Q&A) Transcript
Q3 2024 Sedana Medical AB (publ) Earnings Call(Q&A) Transcript
Sedana Medical AB Earnings Call Transcript: Q3 2024
Record Q3 sales and improved profitability led to raised full-year guidance. U.S. FDA submission will now include European trial data, extending the timeline by a year but strengthening the case. Supplier acquisition is set to boost margins and supply chain control.
Sedana Medical AB Earnings Call Transcript: Q2 2024
Sales grew 20% year-over-year in H1 2024, exceeding guidance, with strong performance in Spain and the UK offsetting a weak quarter in Germany. U.S. clinical trial enrollment is complete, reducing cash burn, and the main supplier acquisition is set to boost margins.